查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446479

原料药 CDMO 的市场规模、份额和趋势分析报告：按产品、合成、药物、应用、工作流程、区域和细分市场进行预测，2024-2030 年

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10个工作天内

价格

原料药CDMO 市场的成长与趋势：

预计2030年，全球原料药CDMO市场规模将达1,645亿美元，2024年至2030年复合年增长率为7.4%。

药品研发投资的增加、专利到期以及对学名药和生物创新的需求不断增长是外包的驱动因素。

小分子药物的增加、原料药(API) 日益复杂以及降低成本的需求正在促进製药业外包服务的快速扩张。合约开发和受託製造厂商(CDMO) 产业的全球影响力和规模仍然分散，只有少数公司实现这一目标。许多公司也提供一站式解决方案作为原料药和药品的综合来源。

医疗产业正在经历一个动态的变化过程，技术快速进步（例如自动化和人工智慧）、对 CRO/CMO/CDMO 的需求以及影响医疗保健市场的研究投资增加等因素。外包活动为许多製药公司带来了好处，包括提高业务效率、扩大地域覆盖、降低资源成本、获得治疗专业知识以及增强按需服务。

COVID-19 大流行为原料药製造商带来了前所未有的期望，管理机械通气重症患者所需药物的需求大幅增加就证明了这一点。由此产生的快速产量成长的需求要求原料药 CDMO 能够适应维持药品供应。全球对新疗法的需求不断增长，疫情后临床研究的增加预计将在未来几年支撑市场。

原料药 CDMO 市场报告亮点

  • 传统原料药药细分市场占主导地位，2022 年收益占有率最大，为 39.8%。
  • 2022 年，创新製药部门占收益占有率为 73.7%。这主要是由于 FDA 对新型分子的核准增加以及创新 API 公司对研发的关注增加。
  • 2022 年，肿瘤学领域以 35.5% 的最高销售份额引领市场。这是由于癌症治疗对高活性 API 的需求不断增加。
  • 由于生物製药在慢性病和感染疾病治疗中的广泛采用，生物技术产业预计在预测期内成长最快，达到 7.0%。
  • 预计临床工作流程领域在预测期内的复合年增长率将达到 7.3%。支持原料药成分需求的临床研究数量的增加是推动该行业成长的主要因素之一。
  • 预计亚太地区在预测期内的复合年增长率将达到 9.1%，是最快的。随着印度和中国等开发中国家的製药公司和受託製造厂商数量迅速增加，该地区很可能在不久的将来超过欧洲和北美。

目录

第一章原料药 CDMO 市场：调查方法与范围

第 2 章原料药 CDMO 市场：执行摘要

  • 市场概述
  • 产品和合成简介
  • 药物及应用概况
  • 工作流程简介
  • 竞争形势概览

第 3 章原料药 CDMO 市场：变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
  • 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 原料药 CDMO市场分析工具

第4章原料药 CDMO市场：产品估算与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 全球原料药CDMO市场、产品前景
  • 2018年至2030年市场规模、预测、趋势分析

第五章原料药 CDMO 市场：综合估算与估算/趋势分析

  • 2023年及2030年合成材料市场占有率
  • 细分仪表板
  • 全球原料药CDMO市场、合成展望
  • 2018年至2030年市场规模、预测、趋势分析

第六章原料药 CDMO 市场：药物预估及趋势分析

  • 2023年及2030年药品市场占有率
  • 细分仪表板
  • 全球原料药CDMO市场，药品前景
  • 2018年至2030年市场规模、预测、趋势分析

第七章原料药 CDMO市场：应用预估与趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球原料药CDMO市场、应用前景
  • 2018年至2030年市场规模、预测、趋势分析

第8章原料药 CDMO市场：工作流程估算与趋势分析

  • 2023 年及 2030 年工作流程市场占有率
  • 细分仪表板
  • 全球原料药CDMO市场、工作流程展望
  • 2018年至2030年市场规模、预测、趋势分析

第 9 章原料药 CDMO 市场：区域业务分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第10章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List Of Key Distributors And Channel Partners
    • Key Customers
    • Key Company Market Share Analysis, 2023
    • Cambrex Corporation
    • Recipharm CP
    • Thermo Fisher Scientific Inc.（Pantheon）
    • CordenPharma International
    • Samsung Biologics
    • Lonza
    • Catalent, Inc.
    • Siegfried Holding AG
    • Piramal Pharma Solutions
    • Boehringer Ingelheim International GmbH
Product Code: GVR-4-68038-282-2

Active Pharmaceutical Ingredient CDMO Market Growth & Trends:

The global active pharmaceutical ingredient CDMO market size was valued at USD 164.5 billion in 2030 and is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030. Increasing pharmaceutical R&D investments, patent expirations, and a rise in demand for generic drugs and biologic innovations propelling outsourcing are the factors driving the market.

The growth of small molecules, rising active pharmaceutical ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the contract development and manufacturing organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

As the healthcare industry is undergoing a process of dynamic change, factors such as rapid technological advancements (e.g., automation & AI), the need for CROs/CMOs/CDMOs, and rising investments in research are influencing the healthcare market. The outsourcing of activities is benefitting many pharmaceutical companies in improving their operational efficiencies, expanding their geographical presence, decreasing resource costs, gaining therapeutic expertise, and enhancing on-demand services.

The COVID-19 pandemic placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving to be better prepared to withstand the pressures of quick scale-up than others. Growing demand for new therapies worldwide and an increase in the conduction of clinical research in the post-pandemic period are expected to support the market in the coming years.

Active Pharmaceutical Ingredient CDMO Market Report Highlights:

  • The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 39.8% in 2022, due to the high adoption of traditional API in majority of pharmaceuticals
  • The innovative drugs segment held 73.7% of the revenue share in 2022. This is largely attributed to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
  • The oncology segment led the market with the highest revenue share of 35.5% in 2022. This is due to the increasing demand for highly potent APIs for cancer therapy
  • The biotech segment is expected to grow at the fastest rate of 7.0% over the forecast period, owing to the high adoption of biopharmaceuticals in the treatment of chronic and infectious diseases
  • The clinical workflow segment is anticipated to witness the fastest CAGR of 7.3% over the forecast period. An increase in the number of clinical research studies supporting the demand for APIs is one of the key factors driving segment growth
  • In Asia Pacific, the market is expected to register the fastest CAGR of 9.1% over the forecast period. Due to the extreme growth in the number of pharmaceutical companies and contract manufacturing organizations in developing countries such as India and China, the region is likely to overtake Europe and North America in the near future

Table of Contents

Chapter 1. Active Pharmaceutical Ingredient CDMO Market: Methodology and Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Synthesis Segment
      • 1.1.1.3. Drug Segment
      • 1.1.1.4. Application segment
      • 1.1.1.5. Workflow segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Active Pharmaceutical Ingredient CDMO Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Products And Synthesis Snapshots
  • 2.3. Drug And Application Snapshot
  • 2.4. Workflow Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increase in pharmaceutical R&D investment
    • 3.4.2. Rapid demand for generic drugs
    • 3.4.3. Patient expiration
    • 3.4.4. Expanding consumption of biopharmaceuticals
  • 3.5. Market Restraint Analysis
    • 3.5.1. Compliance issues while outsourcing
  • 3.6. Active Pharmaceutical Ingredient CDMO Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's Five Forces
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Active Pharmaceutical Ingredient CDMO Market, Product Outlook
  • 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 4.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 4.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Antibody Drug Conjugate (ADC)
      • 4.4.3.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 5. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis

  • 5.1. Synthesis Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Active Pharmaceutical Ingredient CDMO Market, Synthesis Outlook
  • 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 5.4.1. Synthetic
      • 5.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Biotech
      • 5.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 6. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis

  • 6.1. Drug Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Active Pharmaceutical Ingredient CDMO Market, Drug Outlook
  • 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 6.4.1. Innovative
      • 6.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Generics
      • 6.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 7. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Application Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Active Pharmaceutical Ingredient CDMO Market, Application Outlook
  • 7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 7.4.1. Oncology
      • 7.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Hormonal
      • 7.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Glaucoma
      • 7.4.3.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Cardiovascular Disease
      • 7.4.4.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Diabetes
      • 7.4.5.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Others
      • 7.4.6.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 8. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis

  • 8.1. Workflow Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Active Pharmaceutical Ingredient CDMO Market, Workflow Outlook
  • 8.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:
    • 8.4.1. Clinical
      • 8.4.1.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 8.4.2. Commercial
      • 8.4.2.1. Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 9. Active Pharmaceutical Ingredient CDMO Market: Regional Business Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 9.5. North America
    • 9.5.1. U.S.
      • 9.5.1.1. Key Country Dynamics
      • 9.5.1.2. Competitive Scenario
      • 9.5.1.3. Regulatory Framework
      • 9.5.1.4. U.S. Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.5.2. Canada
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Canada Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. UK
      • 9.6.1.1. Key Country Dynamics
      • 9.6.1.2. Competitive Scenario
      • 9.6.1.3. Regulatory Framework
      • 9.6.1.4. UK Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.2. Germany
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Germany Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.3. Spain
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Spain Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.4. France
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Competitive Scenario
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. France Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.5. Italy
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Competitive Scenario
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Italy Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.6. Denmark
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Competitive Scenario
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Denmark Market Estimates And Forecasts 2018 - 2030 (USD Million)
      • 9.6.6.5.
    • 9.6.7. Sweden
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Competitive Scenario
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Sweden Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.6.8. Norway
      • 9.6.8.1. Key Country Dynamics
      • 9.6.8.2. Competitive Scenario
      • 9.6.8.3. Regulatory Framework
      • 9.6.8.4. Norway Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Japan
      • 9.7.1.1. Key Country Dynamics
      • 9.7.1.2. Competitive Scenario
      • 9.7.1.3. Regulatory Framework
      • 9.7.1.4. Japan Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.2. China
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. China Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.3. India
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. India Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.4. South Korea
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. South Korea Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.5. Thailand
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Thailand Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.7.6. Australia
      • 9.7.6.1. Key Country Dynamics
      • 9.7.6.2. Competitive Scenario
      • 9.7.6.3. Regulatory Framework
      • 9.7.6.4. Australia Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Brazil
      • 9.8.1.1. Key Country Dynamics
      • 9.8.1.2. Competitive Scenario
      • 9.8.1.3. Regulatory Framework
      • 9.8.1.4. Brazil Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.2. Mexico
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Competitive Scenario
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Mexico Active Pharmaceutical Ingredient CDMO Market, 2018 - 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Competitive Scenario
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Argentina Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.4. Colombia
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Competitive Scenario
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Colombia Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.8.5. Chile
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Competitive Scenario
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Chile Market Estimates And Forecasts 2018 - 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. South Africa
      • 9.9.1.1. Key Country Dynamics
      • 9.9.1.2. Competitive Scenario
      • 9.9.1.3. Regulatory Framework
      • 9.9.1.4. South Africa Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.2. Saudi Arabia
      • 9.9.2.1. Key Country Dynamics
      • 9.9.2.2. Competitive Scenario
      • 9.9.2.3. Regulatory Framework
      • 9.9.2.4. Saudi Arabia Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.3. UAE
      • 9.9.3.1. Key Country Dynamics
      • 9.9.3.2. Competitive Scenario
      • 9.9.3.3. Regulatory Framework
      • 9.9.3.4. UAE Market Estimates And Forecasts 2018 - 2030 (USD Million)
    • 9.9.4. Kuwait
      • 9.9.4.1. Key Country Dynamics
      • 9.9.4.2. Competitive Scenario
      • 9.9.4.3. Regulatory Framework
      • 9.9.4.4. Kuwait Market Estimates And Forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company /Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List Of Key Distributors And Channel Partners
    • 10.3.2. Key Customers
    • 10.3.3. Key Company Market Share Analysis, 2023
    • 10.3.4. Cambrex Corporation
      • 10.3.4.1. Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Recipharm CP
      • 10.3.5.1. Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Thermo Fisher Scientific Inc. (Pantheon)
      • 10.3.6.1. Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. CordenPharma International
      • 10.3.7.1. Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Samsung Biologics
      • 10.3.8.1. Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Lonza
      • 10.3.9.1. Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Catalent, Inc.
      • 10.3.10.1. Overview
      • 10.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Siegfried Holding AG
      • 10.3.11.1. Overview
      • 10.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.11.3. Product Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Piramal Pharma Solutions
      • 10.3.12.1. Overview
      • 10.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.12.3. Product Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Boehringer Ingelheim International GmbH
      • 10.3.13.1. Overview
      • 10.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.3.13.3. Product Benchmarking
      • 10.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Active Pharmaceutical Ingredient CDMO Market, By Country, 2018 - 2030 (USD Million)
  • Table 3 North America Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 4 North America Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 5 North America Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 6 North America Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 North America Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 8 U.S. Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 10 U.S. Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 11 U.S. Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 13 Canada Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 15 Canada Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 16 Canada Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 18 Europe Active Pharmaceutical Ingredient CDMO Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 20 Europe Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 21 Europe Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 22 Europe Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 24 UK Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 25 UK Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 26 UK Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 27 UK Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 UK Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 29 Germany Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 30 Germany Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 31 Germany Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 32 Germany Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 33 Germany Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 34 France Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 France Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 36 France Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 37 France Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 38 France Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 39 Italy Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 40 Italy Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 41 Italy Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 42 Italy Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 43 Italy Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 44 Spain Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 45 Spain Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 46 Spain Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 47 Spain Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Spain Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 49 Sweden Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 50 Sweden Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 51 Sweden Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 52 Sweden Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 53 Sweden Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 54 Norway Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 55 Norway Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 56 Norway Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 57 Norway Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 58 Norway Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 59 Denmark Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Denmark Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 61 Denmark Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 62 Denmark Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 63 Denmark Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Country, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 70 Japan Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 71 Japan Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 72 Japan Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 73 Japan Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 74 Japan Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 75 China Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 China Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 77 China Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 78 China Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 79 China Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 80 India Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 81 India Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 82 India Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 83 India Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 84 India Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 85 Australia Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 86 Australia Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 87 Australia Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 88 Australia Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 89 Australia Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 90 South Korea Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 91 South Korea Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 92 South Korea Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 93 South Korea Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 South Korea Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 95 Thailand Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 96 Thailand Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 97 Thailand Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 98 Thailand Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 99 Thailand Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 100 Latin America Active Pharmaceutical Ingredient CDMO Market, By Country, 2018 - 2030 (USD Million)
  • Table 101 Latin America Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 102 Latin America Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 103 Latin America Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 104 Latin America Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 105 Latin America Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 106 Brazil Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 107 Brazil Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 108 Brazil Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 109 Brazil Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 110 Brazil Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 111 Mexico Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 112 Mexico Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 113 Mexico Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 114 Mexico Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 115 Mexico Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 116 Argentina Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 117 Argentina Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 118 Argentina Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 119 Argentina Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 120 Argentina Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 121 Colombia Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 122 Colombia Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 123 Colombia Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 124 Colombia Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 125 Colombia Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 126 Chile Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 127 Chile Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 128 Chile Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 129 Chile Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 130 Chile Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 131 MEA Active Pharmaceutical Ingredient CDMO Market, By Country, 2018 - 2030 (USD Million)
  • Table 132 MEA Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 133 MEA Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 134 MEA Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 135 MEA Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 136 MEA Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 137 South Africa Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 138 South Africa Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 139 South Africa Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 140 South Africa Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 141 South Africa Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 144 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 145 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 146 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 147 UAE Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 148 UAE Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 149 UAE Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 150 UAE Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 151 UAE Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Active Pharmaceutical Ingredient CDMO Market, By Product, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Active Pharmaceutical Ingredient CDMO Market, By Synthesis, 2018 - 2030 (USD Million)
  • Table 154 Kuwait Active Pharmaceutical Ingredient CDMO Market, By Drug, 2018 - 2030 (USD Million)
  • Table 155 Kuwait Active Pharmaceutical Ingredient CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 156 Kuwait Active Pharmaceutical Ingredient CDMO Market, By Workflow, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews In North America
  • Fig. 5 Primary Interviews In Europe
  • Fig. 6 Primary Interviews In APAC
  • Fig. 7 Primary Interviews In Latin America
  • Fig. 8 Primary Interviews In MEA
  • Fig. 9 Market Research Approaches
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Modeling For Market Share Assessment
  • Fig. 12 Market Formulation & Validation
  • Fig. 13 Active Pharmaceutical Ingredient CDMO Market: Market Outlook
  • Fig. 14 Active Pharmaceutical Ingredient CDMO Market Competitive Insights
  • Fig. 15 Parent Market Outlook
  • Fig. 16 Related/Ancillary Market Outlook
  • Fig. 17 Penetration And Growth Prospect Mapping
  • Fig. 18 Industry Value Chain Analysis
  • Fig. 19 Active Pharmaceutical Ingredient CDMO Market: Driver Impact
  • Fig. 20 Active Pharmaceutical Ingredient CDMO Market: Restraint Impact
  • Fig. 21 Active Pharmaceutical Ingredient CDMO Market Strategic Initiatives Analysis
  • Fig. 22 Active Pharmaceutical Ingredient CDMO Market: Product Movement Analysis
  • Fig. 23 Active Pharmaceutical Ingredient CDMO Market: Product Outlook And Key Takeaways
  • Fig. 24 Traditional API Market Estimates And Forecast, 2018 - 2030
  • Fig. 25 HP-API Market Estimates And Forecast, 2018 - 2030
  • Fig. 26 Antibody-drug Conjugate Market Estimates And Forecast, 2018 - 2030
  • Fig. 27 Other Products Market Estimates And Forecast, 2018 - 2030
  • Fig. 28 Active Pharmaceutical Ingredient CDMO Market: Synthesis Movement Analysis
  • Fig. 29 Active Pharmaceutical Ingredient CDMO Market: Synthesis Outlook And Key Takeaways
  • Fig. 30 Synthetic Market Estimates And Forecasts, 2018 - 2030
  • Fig. 31 Biotech Market Estimates And Forecasts, 2018 - 2030
  • Fig. 32 Active Pharmaceutical Ingredient CDMO Market: Drug Movement Analysis
  • Fig. 33 Active Pharmaceutical Ingredient CDMO Market: Drug Outlook And Key Takeaways
  • Fig. 34 Innovative Market Estimates And Forecasts, 2018 - 2030
  • Fig. 35 Generics Market Estimates And Forecasts, 2018 - 2030
  • Fig. 36 Active Pharmaceutical Ingredient CDMO Market: Application Movement Analysis
  • Fig. 37 Active Pharmaceutical Ingredient CDMO Market: Application Outlook And Key Takeaways
  • Fig. 38 Oncology Market Estimates And Forecasts, 2018 - 2030
  • Fig. 39 Hormonal Market Estimates And Forecasts, 2018 - 2030
  • Fig. 40 Glaucoma Market Estimates And Forecasts, 2018 - 2030
  • Fig. 41 Cardiovascular Diseases Market Estimates And Forecasts, 2018 - 2030
  • Fig. 42 Diabetes Market Estimates And Forecasts, 2018 - 2030
  • Fig. 43 Others Market Estimates And Forecasts, 2018 - 2030
  • Fig. 44 Active Pharmaceutical Ingredient CDMO Market: Workflow Analysis
  • Fig. 45 Active Pharmaceutical Ingredient CDMO Market: Workflow Outlook And Key Takeaways
  • Fig. 46 Clinical Market Estimates And Forecasts, 2018 - 2030
  • Fig. 47 Commercial Market Estimates And Forecasts, 2018 - 2030
  • Fig. 48 Global Active Pharmaceutical Ingredient CDMO Market: Regional Movement Analysis
  • Fig. 49 Global Active Pharmaceutical Ingredient CDMO Market: Regional Outlook And Key Takeaways
  • Fig. 50 Global Active Pharmaceutical Ingredient CDMO Market Share And Leading Players
  • Fig. 51 North America Market Share And Leading Players
  • Fig. 52 Europe Market Share And Leading Players
  • Fig. 53 Asia Pacific Market Share And Leading Players
  • Fig. 54 Latin America Market Share And Leading Players
  • Fig. 55 Middle East & Africa Market Share And Leading Players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, By Country
  • Fig. 62 North America
  • Fig. 63 North America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 64 U.S.
  • Fig. 65 U.S. Market Estimates And Forecasts, 2018 - 2030
  • Fig. 66 Canada
  • Fig. 67 Canada Market Estimates And Forecasts, 2018 - 2030
  • Fig. 68 Europe
  • Fig. 69 Europe Market Estimates And Forecasts, 2018 - 2030
  • Fig. 70 UK
  • Fig. 71 UK Market Estimates And Forecasts, 2018 - 2030
  • Fig. 72 Germany
  • Fig. 73 Germany Market Estimates And Forecasts, 2018 - 2030
  • Fig. 74 France
  • Fig. 75 France Market Estimates And Forecasts, 2018 - 2030
  • Fig. 76 Italy
  • Fig. 77 Italy Market Estimates And Forecasts, 2018 - 2030
  • Fig. 78 Spain
  • Fig. 79 Spain Market Estimates And Forecasts, 2018 - 2030
  • Fig. 80 Denmark
  • Fig. 81 Denmark Market Estimates And Forecasts, 2018 - 2030
  • Fig. 82 Sweden
  • Fig. 83 Sweden Market Estimates And Forecasts, 2018 - 2030
  • Fig. 84 Norway
  • Fig. 85 Norway Market Estimates And Forecasts, 2018 - 2030
  • Fig. 86 Asia Pacific
  • Fig. 87 Asia Pacific Market Estimates And Forecasts, 2018 - 2030
  • Fig. 88 China
  • Fig. 89 China Market Estimates And Forecasts, 2018 - 2030
  • Fig. 90 Japan
  • Fig. 91 Japan Market Estimates And Forecasts, 2018 - 2030
  • Fig. 92 India
  • Fig. 93 India Market Estimates And Forecasts, 2018 - 2030
  • Fig. 94 Thailand
  • Fig. 95 Thailand Market Estimates And Forecasts, 2018 - 2030
  • Fig. 96 South Korea
  • Fig. 97 South Korea Market Estimates And Forecasts, 2018 - 2030
  • Fig. 98 Australia
  • Fig. 99 Australia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 100 Latin America
  • Fig. 101 Latin America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 102 Brazil
  • Fig. 103 Brazil Market Estimates And Forecasts, 2018 - 2030
  • Fig. 104 Mexico
  • Fig. 105 Mexico Market Estimates And Forecasts, 2018 - 2030
  • Fig. 106 Argentina
  • Fig. 107 Argentina Market Estimates And Forecasts, 2018 - 2030
  • Fig. 108 Colombia
  • Fig. 109 Colombia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 110 Chile
  • Fig. 111 Chile Market Estimates And Forecasts, 2018 - 2030
  • Fig. 112 Middle East And Africa
  • Fig. 113 Middle East And Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 114 South Africa
  • Fig. 115 South Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 116 Saudi Arabia
  • Fig. 117 Saudi Arabia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 118 UAE
  • Fig. 119 UAE Market Estimates And Forecasts, 2018 - 2030
  • Fig. 120 Kuwait
  • Fig. 121 Kuwait Market Estimates And Forecasts, 2018 - 2030
  • Fig. 122 Market Share Of Key Players - Active Pharmaceutical Ingredient CDMO Market